Drug
PM 01183 clinical trials
Also written Lurbinectedin, PM01183 and Zepzelca.
- studies test it
- 53
- open now
- 17
- in phase 3
- 7
- first study started
- 2009
Keep track of what changes. Save the PM 01183 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
52 studies that test it; most in 2023 (7); 1 more planned to start later
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 5 |
| 2022 | 6 |
| 2023 | 7 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 29
- Phase 2
- 31
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 26
PharmaMar (20) · Jazz Pharmaceuticals (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Luye Pharma Group Ltd. (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (1) · Hoffmann-La Roche (1) · Massachusetts General Hospital (1)
Often tested with
Tested in the same studies.
Irinotecan (7) · Paclitaxel (4) · Gemcitabine (3) · Topotecan (3) · Durvalumab (2) · Doxorubicin (2) · Bevacizumab (2) · Cisplatin (2)
Studies
Open first, then newest update. How each study uses PM 01183 is read from its arms, and is right about nine times in ten.
Testing it · 53
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerRecruitingPhase 3Gilead SciencesNCT06801834Written as Lurbinectedin (regions/countries where approved and available)
- Lurbinectedin With Osimertinib in Transformed Small Cell Lung CancerRecruitingPhase 1/2Misty ShieldsNCT07153055Written as Lurbinectedin
- Study of Trilaciclib and LurbinectidinRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT05578326Written as Lurbinectedin
- A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCRecruitingPhase 2Jazz PharmaceuticalsNCT07459634Written as Lurbinectedin
- Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung CancerNot yet recruitingPhase 2Yonsei UniversityNCT07640932Written as Lurbinectedin
- Lurbinectedin in FET-Fused TumorsRecruitingPhase 1/2Children's Hospital of PhiladelphiaNCT05918640Written as Lurbinectedin
- Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPSRecruitingPhase 2Italian Sarcoma GroupNCT07328425Written as Lurbinectedin
- Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT05636111Written as Lurbinectedin
- Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLCRecruitingPhase 2Guangzhou Institute of Respiratory DiseaseNCT06497530Written as Lurbinectedin
- Dose Attenuated Chemotherapy in Compromised Patients With Lung CancerRecruitingPhase 2Fox Chase Cancer CenterNCT05800587Written as Lurbinectedin
- Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing SarcomaRecruitingPhase 1/2Jazz PharmaceuticalsNCT05734066Written as Lurbinectedin
- Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung CancerRecruitingPhase 1Emory UniversityNCT05244239Written as Lurbinectedin
- Patients With High-grade Pancreatic Neuroendocrine TumorsEnrolling by invitationPhase 2National Cancer Center, KoreaNCT07121478Written as Lurbinectedin 4 MG Injection [Zepzelca]
- An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular TypingNot yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07141771Written as Lurbinectedin
- Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCRecruitingPhase 3Luye Pharma Group Ltd.NCT06496048Written as Lurbinectedin
- Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic ImpairmentRecruitingPhase 1PharmaMarNCT05101265Written as Lurbinectedin
- Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.RecruitingPhase 1/2Fundacion OncosurNCT04253145Written as PM 01183
- Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)CompletedPhase 3PharmaMarNCT05153239Written as Lurbinectedin
- Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung CancerActive, not recruitingPhase 2Mayo ClinicNCT04607954Written as Lurbinectedin
- Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair MutationsCompletedPhase 2HonorHealth Research InstituteNCT05229588Written as Lurbinectedin 4 MG Injection [Zepzelca]
See all 53 studies that test PM 01183 →
Given in every arm · 4 — PM 01183 is usual care beside what is tested
- Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)RecruitingPhase 2National Cancer Institute (NCI)NCT06228066Written as Lurbinectedin
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerRecruitingPhase 2AbbVieNCT07155174Written as Lurbinectedin
- A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)RecruitingPhase 1/2Phanes TherapeuticsNCT05652686Written as Lurbinectedin
- A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable SarcomasCompletedPhase 2Massachusetts General HospitalNCT02448537Written as PM01183
As the comparator · 4 — what is tested is compared with PM 01183
- A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerRecruitingPhase 3AbbVieNCT07365241Written as Lurbinectedin
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerRecruitingPhase 3Daiichi SankyoNCT06203210Written as Lurbinectedin
- Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLCRecruitingPhase 1/2VA Office of Research and DevelopmentNCT06681220Written as Lurbinectedin
- Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerActive, not recruitingPhase 3AmgenNCT05740566Written as Lurbinectedin
Codes
What other systems call PM 01183 · ClinicalTrials.gg INT005937
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C568606 | PM 01183 | One source ClinicalTrials.gov |
| RxNorm | 2374729 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.